Our meta-analysis of clinical trials involving patients with heart failure demonstrated some promising evidence to suggest possible beneficial effects of the GLP-1 peptide agonist in improving cardiac function, in both diabetics and nondiabetics. The gene discussed is GCG; the disease is heart failure.